12 Mar 2020
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
Author: admintech | Filed under: Press ReleaseCAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ — Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by…